Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Banco de datos
Tipo del documento
Asunto de la revista
País de afiliación
Intervalo de año de publicación
1.
J Invasive Cardiol ; 22(1): 35-9, 2010 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-20048398

RESUMEN

BACKGROUND: Arterial puncture closure devices have improved time to hemostasis and ambulation after percutaneous coronary intervention (PCI) relative to traditional manual compression, though complication rates for both methods leave room for improvement. In a pilot registry, the authors evaluated a topical hemostatic dressing containing poly-N-acetyl glucosamine (p-GlcNAc) post PCI in fully anticoagulated patients. METHODS AND RESULTS: In 100 patients undergoing PCI via the common femoral artery in the short-stay unit, the p-GlcNAc hemostatic dressing was applied with 15 minutes of manual compression at arterial access sites after arterial sheath removal. Procedural antiplatelet and anticoagulation therapies were aspirin, clopidogrel and bivalirudin. Patients were observed during 2 hours of bed rest and attempted to ambulate 2 hours post hemostasis. Effectiveness was assessed based on times to hemostasis and ambulation. Data were stratified by time elapsed since bivalirudin bolus or discontinuation of infusion (30 minutes, > 30-60 minutes, > 60 minutes). Mean time to hemostasis was 15.5 minutes. Mean time from hemostasis to ambulation was 2.08 hours; 87% of patients ambulated at 2 hours. Sheaths were removed at a mean 40.38 minutes after discontinuing bivalirudin. Anticoagulation status (as assessed by time since discontinuation of bivalirudin) did not influence time to hemostasis or ambulation. There was a single major complication (pseudoaneurysm), two minor rebleeds requiring additional manual compression, and 1 hematoma > 5 cm. CONCLUSIONS: This p-GlcNAc topical hemostatic dressing safely achieved hemostasis at arterial access sites and early ambulation, even with nearly immediate sheath removal after PCI with systemic anticoagulation using bivalirudin.


Asunto(s)
Acetilglucosamina/uso terapéutico , Angioplastia Coronaria con Balón/métodos , Apósitos Biológicos , Arteria Femoral/fisiología , Hemostasis/fisiología , Hemostáticos/uso terapéutico , Flujo Sanguíneo Regional/fisiología , Acetilglucosamina/administración & dosificación , Acetilglucosamina/efectos adversos , Administración Tópica , Anciano , Anticoagulantes/uso terapéutico , Femenino , Hemostáticos/administración & dosificación , Hemostáticos/efectos adversos , Hirudinas , Humanos , Masculino , Fragmentos de Péptidos/uso terapéutico , Proyectos Piloto , Proteínas Recombinantes/uso terapéutico , Estudios Retrospectivos , Trombosis/prevención & control , Factores de Tiempo , Caminata
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA